SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Seres Therapeutics Inc.

(Name of Issuer)

Common Stock, $.001 par value

(Title of Class of Securities)

81750R102

(CUSIP Number)

December 31, 2015

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 81750R102   13G    Page 2 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship Ventures Fund 2007, L.P.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

599,297 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

599,297 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

599,297 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.53%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

PN


CUSIP No. 81750R102   13G    Page 3 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship Ventures 2007 General Partner LLC

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

EACH

REPORTING

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

599,297 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

599,297 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

599,297 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.53%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

OO


CUSIP No. 81750R102   13G    Page 4 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship Ventures Fund IV, L.P.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

11,877,976 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

11,877,976 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

11,877,976 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

30.41%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

PN


CUSIP No. 81750R102   13G    Page 5 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship Ventures Fund IV-Rx, L.P.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

2,205,603 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

2,205,603 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,205,603 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.65%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

PN


CUSIP No. 81750R102   13G    Page 6 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship VentureLabs IV, LLC

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

3,055,556 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

3,055,556 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,055,556 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.82%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

OO


CUSIP No. 81750R102   13G    Page 7 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Flagship Ventures Fund IV General Partner LLC

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

14,083,579 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

14,083,579 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

14,083,579 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

36.06%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

OO


CUSIP No. 81750R102   13G    Page 8 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Noubar B. Afeyan, Ph.D.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

14,682,876 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

14,682,876 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

14,682,876 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

37.59%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IN


CUSIP No. 81750R102   13G    Page 9 of 17

 

  1   

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Edwin M. Kania, Jr.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

(a)  ¨        (b)  x

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

     

SOLE VOTING POWER

 

0

   6   

SHARED VOTING POWER

 

14,682,876 shares

   7   

SOLE DISPOSITIVE POWER

 

0

   8   

SHARED DISPOSITIVE POWER

 

14,682,876 shares

  9

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

14,682,876 shares

10

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

¨

11

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

37.59%

12

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IN


CUSIP No. 81750R102   13G    Page 10 of 17

 

Item 1(a). Name of Issuer:

Seres Therapeutics Inc. (the “Issuer”)

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

215 First Street, Cambridge, Massachusetts 02142

 

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

Flagship Ventures Fund 2007, L.P. (“Flagship 2007 Fund”)

Flagship Ventures 2007 General Partner LLC (“Flagship 2007 GP”)

Flagship Ventures Fund IV, L.P. (“Flagship IV Fund”)

Flagship Ventures Fund IV-Rx, L.P. (“Flagship IV-Rx Fund”)

Flagship VentureLabs IV, LLC (“Flagship VentureLabs IV”)

Flagship Ventures Fund IV General Partner LLC (“Flagship IV GP”)

Noubar B. Afeyan, Ph.D. (“Mr. Afeyan”)

Edwin M. Kania, Jr. (“Mr. Kania”)

 

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

c/o Flagship Ventures

One Memorial Drive, 7th Floor

Cambridge, Massachusetts 02142

 

Item 2(c). Citizenship:

 

  Flagship 2007 Fund    Delaware limited partnership
  Flagship 2007 GP    Delaware limited liability company
  Flagship IV Fund    Delaware limited partnership
  Flagship IV-Rx Fund    Delaware limited partnership
  Flagship VentureLabs IV    Delaware limited liability company
  Flagship IV GP    Delaware limited liability company
  Mr. Afeyan    U.S. citizen
  Mr. Kania    U.S. citizen

 

Item 2(d). Title of Class of Securities:

Common Stock, $.001 par value (“Common Stock”).

 

Item 2(e). CUSIP Number:

81750R102.


CUSIP No. 81750R102   13G    Page 11 of 17

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

Item 4. Ownership.

 

  (a) Amount Beneficially Owned:

As of December 31, 2015: (i) Flagship 2007 Fund was the record owner of 599,297 shares of Common Stock (the “Fund 2007 Shares”), (ii) Flagship IV Fund was the record owner of 8,822,420 shares of Common Stock (the “Fund IV Shares”), (iii) Flagship IV-Rx Fund was the record owner of 2,205,603 shares of Common Stock (the “Fund IV-Rx Shares”) and (iv) Flagship VentureLabs IV was the record owner of 3,055,556 shares of Common Stock (the “VentureLabs IV Shares” and, collectively with the Fund IV Shares and the Fund IV-Rx Shares, the “Flagship IV Shares”). The Fund 2007 Shares and the Flagship IV Shares are collectively referred to herein as the “Shares.”

Flagship 2007 GP is the general partner of Flagship 2007 Fund and, as such, may be deemed to beneficially own the Fund 2007 Shares.

Flagship IV Fund is the manager of Flagship VentureLabs IV and, as such, may be deemed to beneficially own the VentureLabs IV Shares.

Flagship IV GP is the general partner of each of Flagship IV Fund and Flagship IV-Rx Fund and, as such, may be deemed to beneficially own the Flagship IV Shares.

Messrs. Afeyan and Kania are the managers of each of Fund 2007 GP and Fund IV GP and have shared voting and dispositive power over the Shares. Accordingly, Messrs. Afeyan and Kania may be deemed to beneficially own the Shares.

Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest in such Shares.

The ownership percentages reported above are based on an aggregate of 39,055,767 shares of Common Stock outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015.

 

  (b) Percent of Class:

 

Flagship 2007 Fund   1.53%
Flagship 2007 GP   1.53%
Flagship IV Fund   30.41%
Flagship IV-Rx Fund   5.65%
Flagship VentureLabs IV   7.82%
Flagship IV GP   36.06%
Mr. Afeyan   37.59%
Mr. Kania   37.59%

 

  (c) Number of shares as to which such person has:


CUSIP No. 81750R102   13G    Page 12 of 17

 

(i)   sole power to vote or to direct the vote:
  Flagship 2007 Fund   0
  Flagship 2007 GP   0
  Flagship IV Fund   0
  Flagship IV-Rx Fund   0
  Flagship VentureLabs IV   0
  Flagship IV GP   0
  Mr. Afeyan   0
  Mr. Kania   0
(ii)   shared power to vote or to direct the vote:
  Flagship 2007 Fund   599,297
  Flagship 2007 GP   599,297
  Flagship IV Fund   11,877,976
  Flagship IV-Rx Fund   2,205,603
  Flagship VentureLabs IV   3,055,556
  Flagship IV GP   14,083,579
  Mr. Afeyan   14,682,876
  Mr. Kania   14,682,876
(iii)   sole power to dispose or to direct the disposition of:
  Flagship 2007 Fund   0
  Flagship 2007 GP   0
  Flagship IV Fund   0
  Flagship IV-Rx Fund   0
  Flagship VentureLabs IV   0
  Flagship IV GP   0
  Mr. Afeyan   0
  Mr. Kania   0
(iv)   shared power to dispose or to direct the disposition of:
  Flagship 2007 Fund   599,297
  Flagship 2007 GP   599,297
  Flagship IV Fund   11,877,976
  Flagship IV-Rx Fund   2,205,603
  Flagship VentureLabs IV   3,055,556
  Flagship IV GP   14,083,579
  Mr. Afeyan   14,682,876
  Mr. Kania   14,682,876

 

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.


CUSIP No. 81750R102   13G    Page 13 of 17

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

Each of the Reporting Persons expressly disclaims membership in a “Group” as used in Rule 13d-5(b).

 

Item 9. Notice of Dissolution of Group.

Not applicable.

 

Item 10. Certification.

Not applicable. This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d–1(c).

Material to be Filed as Exhibits.

Exhibit 1 – Agreement regarding filing of joint Schedule 13G.


CUSIP No. 81750R102   13G    Page 14 of 17

 

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 16, 2016

FLAGSHIP VENTURES 2007 FUND, L.P.

 

By:   Flagship Ventures 2007 General Partner LLC
  General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV, L.P.
By:   Flagship Ventures Fund IV General Partner LLC
  General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV-Rx, L.P.
By:   Flagship Ventures Fund IV General Partner LLC
  General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager


CUSIP No. 81750R102   13G    Page 15 of 17

 

FLAGSHIP VENTURELABS IV, LLC
By:   Flagship Ventures Fund IV, L.P.
 

Manager

  By:   Flagship Ventures Fund IV General Partner LLC
    General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager

/s/ Noubar B. Afeyan, Ph.D.

Noubar B. Afeyan, Ph.D.

/s/ Edwin M. Kania, Jr.

Edwin M. Kania, Jr.
EX-99.1
CUSIP No. 81750R102   13G    Page 16 of 17

 

EXHIBIT 1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Seres Therapeutics Inc.

EXECUTED this 16th day of February, 2016.

FLAGSHIP VENTURES 2007 FUND, L.P.

 

By:   Flagship Ventures 2007 General Partner LLC
 

General Partner

  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV, L.P.
By:   Flagship Ventures Fund IV General Partner LLC General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV-Rx, L.P.
By:   Flagship Ventures Fund IV General Partner LLC General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager


CUSIP No. 81750R102   13G    Page17 of 17

 

FLAGSHIP VENTURELABS IV, LLC

 

By:   Flagship Ventures Fund IV, L.P.
 

Manager

  By:   Flagship Ventures Fund IV General Partner LLC
    General Partner
    By:  /s/ Noubar B. Afeyan, Ph.D.              
            Noubar B. Afeyan, Ph.D.
            Manager
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager

/s/ Noubar B. Afeyan, Ph.D.

Noubar B. Afeyan, Ph.D.

/s/ Edwin M. Kania, Jr.

Edwin M. Kania, Jr.